Loading...
Market
What will be the market share of GLP-1 medications in Europe by end of Q2 2025?
2
Resolution / Starting Odds
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Market research reports from firms like IQVIA or Frost & Sullivan
Story
Novo Nordisk's GLP-1 Wegovy Receives EMA Approval for Heart Failure Label Update on Thursday
Sep 19, 2024, 08:00 PM
Novo Nordisk, the Danish drugmaker, announced that its drug Wegovy has received a positive opinion from the European Medicines Agency for a label update. The update will reflect reduced heart failure symptoms and improved physical function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The recommendation, announced on Thursday, is based on results from the STEP HFpEF trials. Wegovy is the first GLP-1 medication to receive such an endorsement for obesity-related heart failure.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%